Protagonist Therapeutics, Inc

For the period ended Mar 31, 2026. Filed May 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)


· · March 31, · · December 31,
· · 2026 · · 2025
Assets
Current assets:
Cash and cash equivalents	$193,712	$128,390
Marketable securities	354,074	438,974
Receivable from collaboration partner	53,663	121
Prepaid expenses and other current assets	12,006	10,089
Total current assets	613,455	577,574
Marketable securities - noncurrent	72,548	78,638
Property and equipment, net	3,778	3,860
Restricted cash - noncurrent	288	287
Operating lease right-of-use asset	7,390	7,829
Total assets	$697,459	$668,188
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$8,437	$5,339
Accrued expenses and other payables	17,491	28,269
Deferred revenue	6,282	9,550
Operating lease liability	2,339	2,283
Total current liabilities	34,549	45,441
Operating lease liability - noncurrent	7,437	8,040
Total liabilities	41,986	53,481
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock, $0.00001 par value, 180,000,000 shares authorized; 64,227,057 and 62,577,897 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	1	1
Additional paid-in capital	1,122,629	1,084,736
Accumulated other comprehensive (loss) income	(269)	641
Accumulated deficit	(466,888)	(470,671)
Total stockholders’ equity	655,473	614,707
Total liabilities and stockholders’ equity	$697,459	$668,188

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.